


UK Standards for Microbiology Investigations

Review of users' comments received by
Working group for microbiology standards in clinical
bacteriology

ID 24 identification of *Salmonella* species



"NICE has renewed accreditation of the process used by **Public Health England (PHE)** to produce **UK Standards for Microbiology Investigations**. The renewed accreditation is valid until **30 June 2021** and applies to guidance produced using the processes described in **UK standards for microbiology investigations (UKSMIs) Development process, S9365', 2016**. The original accreditation term began in **July 2011**."

This publication was created by Public Health England (PHE) in partnership with the NHS. Recommendations are listed as ACCEPT/ PARTIAL ACCEPT/DEFER/ NONE or PENDING

Proposal for changes

Comment number	2		
Date received	01/12/2020	Professional body	Society for Applied Microbiology
Section	See below		
<p>a) Section for comments 4.1 Taxonomy/characteristics</p> <p>Comments/evidence Section 4.1 lists Salmonella typhi Salmonella enteritidis, Salmonella choleraesuis and Salmonella typhimurium as valid species names but in the rest of the document these are all given as serovars Salmonella Typhi, Salmonella Enteritidis, Salmonella Choleraesuis and Salmonella Typhimurium, ie as serovars of Salmonella enterica not as species. This is inconsistent and confusing, requiring some explanatory note in the document.</p>			
<p>b) Section for comments 8.2 Primary isolation media</p> <p>Comments/evidence Section 8.2 on Primary Isolation media states Blood agar incubated in 5 to 10% CO2 at 35 to 37°C for 18 to 24hr. However, incubation in air at 35 to 37°C for 18 to 24hr has been found to be just as effective and less costly.</p>			
<p>c) Section for comments Section 8.4.3 Rapid Molecular Methods</p> <p>Comments/evidence Suggest that Section 8.4.3 on Rapid Molecular Methods is tabulated with advantages and limitations columns. Also, it states that 'more evaluation needs to be done with varieties' Is there a future commitment to preparing SMIS for these molecular tests and request more clarity on who will undertake this work?</p>			
<p>d) Section for comments 9.5 Public Health England</p> <p>Comments/evidence Suggest clarifying what SGSS reporting stands for.</p>			
<p>e) Section for comments Appendix 1</p> <p>Comments/evidence Suggest adding text at the bottom that clarifies the relationship to molecular testing.</p>			
Evidence			
-			
Financial barriers			
No			
Health benefits			

No

Are you aware of any interested parties we should consider consulting with on the development of this document?

No

Recommended action

a) ACCEPT

The document has been updated with serotypes and serovars.

b) ACCEPT

This has been updated in the document.

c) NONE

Not relevant for this UK SMI.

d) ACCEPT

This has been updated in the document to clarify the meaning of SGSS.

e) ACCEPT

Appendix 1 has been updated in the document to include molecular testing.

Respondents indicating they were happy with the contents of the document

Overall number of comments: 0